{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T20:01:58Z","timestamp":1771272118585,"version":"3.50.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100014841","name":"Medac","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014841","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s12325-025-03450-x","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T08:25:17Z","timestamp":1764923117000},"page":"633-649","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-Utility Analysis of Subcutaneous Methotrexate in the Treatment of Patients with Rheumatoid Arthritis in the UK"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4620-8893","authenticated-orcid":false,"given":"Matthew","family":"Tucker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8065-755X","authenticated-orcid":false,"given":"Johannes","family":"P\u00f6hlmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6991-0473","authenticated-orcid":false,"given":"Kristin","family":"Grabe-Heyne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6238-7554","authenticated-orcid":false,"given":"Annelie","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8435-8756","authenticated-orcid":false,"given":"Anja","family":"Rasch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7939-7204","authenticated-orcid":false,"given":"Mondher","family":"Toumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5132-3972","authenticated-orcid":false,"given":"Muhammad K.","family":"Nisar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9873-7507","authenticated-orcid":false,"given":"Richard F.","family":"Pollock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"3450_CR1","doi-asserted-by":"crossref","unstructured":"Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018;320:1360\u201372. https:\/\/doi.org\/10\/gfcpch.","DOI":"10.1001\/jama.2018.13103"},{"key":"3450_CR2","doi-asserted-by":"crossref","unstructured":"Smith MH, Berman JR. What is rheumatoid arthritis? JAMA. 2022;327:1194. https:\/\/doi.org\/10\/gt3jcx.","DOI":"10.1001\/jama.2022.0786"},{"key":"3450_CR3","unstructured":"NICE. Prevalence and incidence | background information | rheumatoid arthritis [Internet]. NICE Clin. Knowl. Summ. [cited 2025 May 16]. https:\/\/cks.nice.org.uk\/topics\/rheumatoid-arthritis\/background-information\/prevalence-incidence\/. Accessed 16 May 2025."},{"key":"3450_CR4","first-page":"455","volume":"97","author":"A Wasserman","year":"2018","unstructured":"Wasserman A. Rheumatoid arthritis: common questions about diagnosis and management. Am Fam Physician. 2018;97:455\u201362.","journal-title":"Am Fam Physician"},{"key":"3450_CR5","doi-asserted-by":"crossref","unstructured":"Pugner KM, Scott DI, Holmes JW, Hieke K. The costs of rheumatoid arthritis: an international long-term view. Semin Arthritis Rheum. 2000;29:305\u201320. https:\/\/doi.org\/10\/c89s7p.","DOI":"10.1016\/S0049-0172(00)80017-7"},{"key":"3450_CR6","doi-asserted-by":"crossref","unstructured":"Matcham F, Scott IC, Rayner L, Hotopf M, Kingsley GH, Norton S, et al. The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis. Semin Arthritis Rheum. 2014;44:123\u201330. https:\/\/doi.org\/10\/f2vsgd.","DOI":"10.1016\/j.semarthrit.2014.05.001"},{"key":"3450_CR7","doi-asserted-by":"crossref","unstructured":"Chen L, Wu B, Mo L, Chen H, Zhao Y, Tan T, et al. Associations between biological ageing and the risk of, genetic susceptibility to, and life expectancy associated with rheumatoid arthritis: a secondary analysis of two observational studies. Lancet Healthy Longev. 2024;5:e45\u201355. https:\/\/doi.org\/10\/g88ckz.","DOI":"10.1016\/S2666-7568(23)00220-9"},{"key":"3450_CR8","unstructured":"NICE. Rheumatoid arthritis in adults: management [Internet]. London: NICE; 2018 July. Report No.: NG100. https:\/\/www.nice.org.uk\/guidance\/ng100. Accessed 27 May 2025."},{"key":"3450_CR9","doi-asserted-by":"crossref","unstructured":"Tanaka Y. Subcutaneous injection of methotrexate: advantages in the treatment of rheumatoid arthritis. Mod Rheumatol. 2023;33:633\u20139. https:\/\/doi.org\/10\/gthmf4.","DOI":"10.1093\/mr\/roac156"},{"key":"3450_CR10","doi-asserted-by":"crossref","unstructured":"Hazlewood GS, Thorne JC, Pope JE, Lin D, Tin D, Boire G, et al. The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis. Ann Rheum Dis. 2016;75:1003\u20138. https:\/\/doi.org\/10\/f8prp9.","DOI":"10.1136\/annrheumdis-2014-206504"},{"key":"3450_CR11","doi-asserted-by":"crossref","unstructured":"Bianchi G, Caporali R, Todoerti M, Mattana P. Methotrexate and rheumatoid arthritis: current evidence regarding subcutaneous versus oral routes of administration. Adv Ther. 2016;33:369\u201378. https:\/\/doi.org\/10\/f8jhk6.","DOI":"10.1007\/s12325-016-0295-8"},{"key":"3450_CR12","doi-asserted-by":"crossref","unstructured":"Li D, Yang Z, Kang P, Xie X. Subcutaneous administration of methotrexate at high doses makes a better performance in the treatment of rheumatoid arthritis compared with oral administration of methotrexate: a systematic review and meta-analysis. Semin Arthritis Rheum. 2016;45:656\u201362. https:\/\/doi.org\/10\/gqq2nw.","DOI":"10.1016\/j.semarthrit.2015.11.004"},{"key":"3450_CR13","unstructured":"Joint Formulary Committee. British National Formulary [Internet]. 2025 [cited 2025 May 2]. https:\/\/bnf.nice.org.uk\/. Accessed 2 May 2025."},{"key":"3450_CR14","doi-asserted-by":"crossref","unstructured":"Grimm SE, Wijnen B, Riemsma R, Fayter D, Armstrong N, Ahmadu C, et al. Filgotinib for moderate to severe rheumatoid arthritis: an evidence review group perspective of a NICE single technology appraisal. PharmacoEconomics. 2021;39:1397\u2013410. https:\/\/doi.org\/10\/g9r5jh.","DOI":"10.1007\/s40273-021-01080-z"},{"key":"3450_CR15","doi-asserted-by":"crossref","unstructured":"Incerti D, Hernandez EJM, Tkacz J, Jansen JP, Collier D, Gharaibeh M, et al. The effect of dose escalation on the cost-effectiveness of etanercept and adalimumab with methotrexate among patients with moderate to severe rheumatoid arthritis. J Manag Care Spec Pharm. 2020;26:1236\u201342. https:\/\/doi.org\/10\/gnwr54.","DOI":"10.18553\/jmcp.2020.26.10.1236"},{"key":"3450_CR16","doi-asserted-by":"crossref","unstructured":"Tan C, Luo X, Li S, Yi L, Zeng X, Peng L, et al. Sequences of biological treatments for patients with moderate-to-severe rheumatoid arthritis in the era of treat-to-target in China: a cost-effectiveness analysis. Clin Rheumatol. 2022;41:63\u201373. https:\/\/doi.org\/10\/gschrz.","DOI":"10.1007\/s10067-021-05876-4"},{"key":"3450_CR17","doi-asserted-by":"crossref","unstructured":"Tian L, Xiong X, Guo Q, Chen Y, Wang L, Dong P, et al. Cost-effectiveness of tofacitinib for patients with moderate-to-severe rheumatoid arthritis in China. PharmacoEconomics. 2020;38:1345\u201358. https:\/\/doi.org\/10\/gscpdw.","DOI":"10.1007\/s40273-020-00961-z"},{"key":"3450_CR18","doi-asserted-by":"crossref","unstructured":"Hirose T, Kawaguchi I, Murata T, Atsumi T. Cost-effectiveness analysis of etanercept 25\u00a0mg maintenance therapy after treatment with etanercept 50\u00a0mg for moderate rheumatoid arthritis in the PRESERVE trial in Japan. Value Health Reg Issues. 2022;28:105\u201311. https:\/\/doi.org\/10\/g9r5js.","DOI":"10.1016\/j.vhri.2021.06.012"},{"key":"3450_CR19","doi-asserted-by":"crossref","unstructured":"Lu L, Peters J, Roome C, Stein K. Cost-effectiveness analysis of degarelix for advanced hormone-dependent prostate cancer. BJU Int. 2012;109:1183\u201392. https:\/\/doi.org\/10\/czwj3s.","DOI":"10.1111\/j.1464-410X.2011.10434.x"},{"key":"3450_CR20","doi-asserted-by":"crossref","unstructured":"Cremaschi A, van den Boom W, Ng NBH, Franzolini B, Tan KB, Chan JKY, et al. Postpartum screening for type 2 diabetes in women with a history of gestational diabetes mellitus: a cost-effectiveness analysis in Singapore. Value Health Reg Issues. 2025;45:101048. https:\/\/doi.org\/10\/g99v5m.","DOI":"10.1016\/j.vhri.2024.101048"},{"key":"3450_CR21","doi-asserted-by":"crossref","unstructured":"Di Fusco M, Marczell K, Deger KA, Moran MM, Wiemken TL, Cane A, et al. Public health impact of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in the first year of rollout in the United States. J Med Econ. 2022;25:605\u201317. https:\/\/doi.org\/10\/gp5r2w.","DOI":"10.1080\/13696998.2022.2071427"},{"key":"3450_CR22","doi-asserted-by":"crossref","unstructured":"Scholz S, Mittendorf T. Modeling rheumatoid arthritis using different techniques\u2014a review of model construction and results. Health Econ Rev. 2014;4:18. https:\/\/doi.org\/10\/g9zxf2.","DOI":"10.1186\/s13561-014-0018-2"},{"key":"3450_CR23","doi-asserted-by":"crossref","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Health Policy Open. 2022;3:100063. https:\/\/doi.org\/10\/qc4m.","DOI":"10.1016\/j.hpopen.2021.100063"},{"key":"3450_CR24","doi-asserted-by":"crossref","unstructured":"Arnett FC, Edworthy SM, Bloch DA, Mcshane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315\u201324. https:\/\/doi.org\/10\/cr9x3k.","DOI":"10.1002\/art.1780310302"},{"key":"3450_CR25","doi-asserted-by":"crossref","unstructured":"Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23:137\u201345. https:\/\/doi.org\/10\/c367fk.","DOI":"10.1002\/art.1780230202"},{"key":"3450_CR26","first-page":"789","volume":"9","author":"JF Fries","year":"1982","unstructured":"Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol. 1982;9:789\u201393.","journal-title":"J Rheumatol"},{"key":"3450_CR27","unstructured":"NICE. Guide to the methods of technology appraisal 2013 [Internet]. London: NICE; 2013 Apr. Report No.: PMG9. https:\/\/www.nice.org.uk\/process\/pmg9\/chapter\/the-reference-case#discounting. Accessed 27 May 2025."},{"key":"3450_CR28","unstructured":"NICE. Assessing cost effectiveness [Internet]. London: National Institute for Health and Care Excellence; 2012 Nov. Report No.: PMG6. https:\/\/www.nice.org.uk\/process\/pmg6\/chapter\/assessing-cost-effectiveness. Accessed 8 July 2024."},{"key":"3450_CR29","unstructured":"NICE. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed [Internet]. London: National Institute for Health and Care Excellence; 2016 Jan. Report No.: TA375. https:\/\/www.nice.org.uk\/guidance\/ta375. Accessed 20 May 2025."},{"key":"3450_CR30","doi-asserted-by":"crossref","unstructured":"Adas M, Dey M, Norton S, Lempp H, Buch MH, Cope A, et al. What role do socioeconomic and clinical factors play in disease activity states in rheumatoid arthritis? Data from a large UK early inflammatory arthritis audit. RMD Open. 2024;10:e004180. https:\/\/doi.org\/10\/g9sqr2.","DOI":"10.1136\/rmdopen-2024-004180"},{"key":"3450_CR31","doi-asserted-by":"crossref","unstructured":"Russell MD, Gibson M, Zuckerman B, Kumar K, Dubey S, Adas MA, et al. Factors associated with biological and targeted synthetic disease-modifying antirheumatic drug initiation for rheumatoid arthritis in underserved patient groups in England and Wales, UK: a national cohort study. Lancet Rheumatol. 2025;7:e44\u201354. https:\/\/doi.org\/10\/g9sqr9.","DOI":"10.1016\/S2665-9913(24)00221-2"},{"key":"3450_CR32","unstructured":"Tsoi MF, Kearsley-Fleet L, Azadbakht N, Watson K, Hyrich KL, Bluett J, et al. Association between body weight and tocilizumab effectiveness in rheumatoid arthritis: results from the BSRBR-RA. Rheumatol Oxf Engl. 2025;64:477\u201383. https:\/\/doi.org\/10\/g9sqsb."},{"key":"3450_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0221823","volume":"14","author":"AM Bujor","year":"2019","unstructured":"Bujor AM, Janjua S, LaValley MP, Duran J, Braun J, Felson DT. Comparison of oral versus parenteral methotrexate in the treatment of rheumatoid arthritis: a meta-analysis. PLoS ONE. 2019;14:e0221823. https:\/\/doi.org\/10.1371\/journal.pone.0221823.","journal-title":"PLoS ONE"},{"key":"3450_CR34","doi-asserted-by":"crossref","unstructured":"Senbel E, Trop\u00e9 S, Herman-Demars H, Zinovieva E, Courbeyrette A, Clerson P, et al. Benefits of switch from oral to subcutaneous route on adherence to methotrexate in patients with rheumatoid arthritis in real life setting. Patient Prefer Adherence. 2021;15:751\u201360. https:\/\/doi.org\/10\/gthmfq.","DOI":"10.2147\/PPA.S301010"},{"key":"3450_CR35","unstructured":"Office for National Statistics. National life tables: UK [Internet]. 2025 [cited 2025 May 20]. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/lifeexpectancies\/datasets\/nationallifetablesunitedkingdomreferencetables. Accessed 20 May 2025."},{"key":"3450_CR36","doi-asserted-by":"publisher","first-page":"iii-1","DOI":"10.3310\/hta8110","volume":"8","author":"P Barton","year":"2004","unstructured":"Barton P, Jobanputra P, Wilson J, Bryan S, Burls A. The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. Health Technol Assess. 2004;8:iii-1\u201391. https:\/\/doi.org\/10.3310\/hta8110.","journal-title":"Health Technol Assess"},{"key":"3450_CR37","doi-asserted-by":"crossref","unstructured":"Braun J, K\u00e4stner P, Flaxenberg P, W\u00e4hrisch J, Hanke P, Demary W, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 2008;58:73\u201381. https:\/\/doi.org\/10\/chhp6q.","DOI":"10.1002\/art.23144"},{"key":"3450_CR38","doi-asserted-by":"crossref","unstructured":"van Roon EN, Jansen TLTA, Mourad L, Houtman PM, Bruyn GAW, Griep EN, et al. Leflunomide in active rheumatoid arthritis: a prospective study in daily practice. Br J Clin Pharmacol. 2004;57:790\u20137. https:\/\/doi.org\/10\/bqhfxr.","DOI":"10.1111\/j.1365-2125.2004.02075.x"},{"key":"3450_CR39","doi-asserted-by":"crossref","unstructured":"Schiff MH, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis. 2008;67:1096\u2013103. https:\/\/doi.org\/10\/frddrb.","DOI":"10.1136\/ard.2007.080002"},{"key":"3450_CR40","unstructured":"Office for National Statistics. Consumer price inflation tables [Internet]. 2025 [cited 2025 May 30]. https:\/\/www.ons.gov.uk\/economy\/inflationandpriceindices\/datasets\/consumerpriceinflation. Accessed 30 May 2025."},{"key":"3450_CR41","unstructured":"NHS Electronic Drug Tariff [Internet]. [cited 2025 July 14]. https:\/\/www.drugtariff.nhsbsa.nhs.uk\/#\/00894899-DC\/DC00894895\/Home. Accessed 14 July 2025."},{"key":"3450_CR42","unstructured":"Jones K, Weatherly HLA, Birch S, Castelli A, Chalkley MJ, Dargan A, et al. Unit Costs of Health and Social Care 2024 [Internet]. Kent, UK, and York, UK: Personal Social Services Research Unit; 2025 [cited 2025 May 20]. https:\/\/kar.kent.ac.uk\/109563\/. Accessed 20 May 2025."},{"key":"3450_CR43","unstructured":"NICE. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor [Internet]. London: NICE; 2010 Aug. Report No.: TA195. https:\/\/www.nice.org.uk\/guidance\/ta195\/history. Accessed 10 July 2025."},{"key":"3450_CR44","doi-asserted-by":"crossref","unstructured":"Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z, Routh K, et al. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. Health Technol Assess. 2011;15:1\u2013278. https:\/\/doi.org\/10\/pvts.","DOI":"10.3310\/hta15140"},{"key":"3450_CR45","doi-asserted-by":"crossref","unstructured":"Duquesne J, Mazuir E, Price D, Finckh A, Bouget V. Large-scale real-world data depicts the complexity of DMARDs treatment sequences in rheumatoid arthritis. Ann Rheum Dis. Barcelona: EULAR; 2025. p. 688. https:\/\/doi.org\/10\/g9r6xp.","DOI":"10.1016\/j.ard.2025.05.847"},{"key":"3450_CR46","doi-asserted-by":"crossref","unstructured":"Diamantopoulos A, Finckh A, Huizinga T, Sungher DK, Sawyer L, Neto D, et al. Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK. PharmacoEconomics. 2014;32:775\u201387. https:\/\/doi.org\/10\/f6n82v.","DOI":"10.1007\/s40273-014-0165-7"},{"key":"3450_CR47","unstructured":"Office for National Statistics. National life tables [Internet]. 2025 [cited 2025 Jan 16]. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/lifeexpectancies\/datasets\/nationallifetablesunitedkingdomreferencetables. Accessed 16 Jan 2025."},{"key":"3450_CR48","doi-asserted-by":"crossref","unstructured":"Heckert SL, Maassen JM, Cessie S le, Goekoop-Ruiterman YPM, G\u00fcler-Y\u00fcksel M, Lems W, et al. Long-term mortality in treated-to-target RA and UA: results of the BeSt and IMPROVED cohort. Ann Rheum Dis. 2024;83:161\u20138. https:\/\/doi.org\/10\/g9sqr6.","DOI":"10.1136\/ard-2023-224814"},{"key":"3450_CR49","doi-asserted-by":"crossref","unstructured":"Fitzpatrick R, Scott DG, Keary I. Cost-minimisation analysis of subcutaneous methotrexate versus biologic therapy for the treatment of patients with rheumatoid arthritis who have had an insufficient response or intolerance to oral methotrexate. Clin Rheumatol. 2013;32:1605\u201312. https:\/\/doi.org\/10\/f5dfs9.","DOI":"10.1007\/s10067-013-2318-z"},{"key":"3450_CR50","doi-asserted-by":"crossref","unstructured":"Stevenson MD, Wailoo AJ, Tosh JC, Hernandez-Alava M, Gibson LA, Stevens JW, et al. The cost-effectiveness of sequences of biological disease-modifying antirheumatic drug treatment in England for patients with rheumatoid arthritis who can tolerate methotrexate. J Rheumatol. 2017;44:973\u201380. https:\/\/doi.org\/10\/gbp383.","DOI":"10.3899\/jrheum.160941"},{"key":"3450_CR51","doi-asserted-by":"crossref","unstructured":"Amos RS, Pullar T, Bax DE, Situnayake D, Capell HA, McConkey B. Sulphasalazine for rheumatoid arthritis: toxicity in 774 patients monitored for one to 11\u00a0years. BMJ. 1986;293:420\u20133. https:\/\/doi.org\/10\/d77dg4.","DOI":"10.1136\/bmj.293.6544.420"},{"key":"3450_CR52","doi-asserted-by":"crossref","unstructured":"Soliman MM, Ashcroft DM, Watson KD, Lunt M, Symmons DPM, Hyrich KL, et al. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2011;70:583\u20139. https:\/\/doi.org\/10\/dw7pcf.","DOI":"10.1136\/ard.2010.139774"},{"key":"3450_CR53","doi-asserted-by":"crossref","unstructured":"Bergrath E, Gerber RA, Gruben D, Lukic T, Makin C, Wallenstein G. Tofacitinib versus biologic treatments in moderate-to-severe rheumatoid arthritis patients who have had an inadequate response to nonbiologic DMARDs: systematic literature review and network meta-analysis. Int J Rheumatol. 2017;2017:8417249. https:\/\/doi.org\/10\/f9xhk4.","DOI":"10.1155\/2017\/8417249"},{"key":"3450_CR54","doi-asserted-by":"crossref","unstructured":"Pope JE, Khanna D, Norrie D, Ouimet JM. The minimally important difference for the health assessment questionnaire in rheumatoid arthritis clinical practice is smaller than in randomized controlled trials. J Rheumatol. 2009;36:254\u20139. https:\/\/doi.org\/10\/bhcv35.","DOI":"10.3899\/jrheum.080479"},{"key":"3450_CR55","doi-asserted-by":"crossref","unstructured":"Wailoo AJ, Bansback N, Brennan A, Michaud K, Nixon RM, Wolfe F. Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis. Arthritis Rheum. 2008;58:939\u201346. https:\/\/doi.org\/10\/ccd8qw.","DOI":"10.1002\/art.23374"},{"key":"3450_CR56","doi-asserted-by":"crossref","unstructured":"Tanno M, Nakamura I, Ito K, Tanaka H, Ohta H, Kobayashi M, et al. Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis. Mod Rheumatol. 2006;16:77\u201384. https:\/\/doi.org\/10\/bzk2ft.","DOI":"10.3109\/s10165-006-0461-y"},{"key":"3450_CR57","doi-asserted-by":"crossref","unstructured":"Marra CA, Marion SA, Guh DP, Najafzadeh M, Wolfe F, Esdaile JM, et al. Not all \u201cquality-adjusted life years\u201d are equal. J Clin Epidemiol. 2007;60:616\u201324. https:\/\/doi.org\/10\/bj2cr3.","DOI":"10.1016\/j.jclinepi.2006.09.006"},{"key":"3450_CR58","doi-asserted-by":"crossref","unstructured":"Drummond MF, Barbieri M, Wong JB. Analytic choices in economic models of treatments for rheumatoid arthritis: what makes a difference? Med Decis Mak. 2005;25:520\u201333. https:\/\/doi.org\/10\/b6txnx.","DOI":"10.1177\/0272989X05280561"},{"key":"3450_CR59","doi-asserted-by":"crossref","unstructured":"Sokka T, Hakkinen A, Krishnan E, Hannonen P. Similar prediction of mortality by the health assessment questionnaire in patients with rheumatoid arthritis and the general population. Ann Rheum Dis. 2004;63:494\u20137. https:\/\/doi.org\/10\/dm24w6.","DOI":"10.1136\/ard.2003.009530"},{"key":"3450_CR60","doi-asserted-by":"crossref","unstructured":"Qiao L, Hu J, Ou D, Liu M, Shi X, Li X, et al. Comparison of the efficacy and safety of methotrexate injection and methotrexate tablets in active RA. Rheumatol Oxf Engl. 2025;64:3426\u201333. https:\/\/doi.org\/10\/g9sqr8.","DOI":"10.1093\/rheumatology\/keaf054"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03450-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03450-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03450-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T19:03:25Z","timestamp":1771268605000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03450-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["3450"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03450-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"27 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Matthew Tucker and Johannes P\u00f6hlmann are employed by, and Richard F. Pollock is a director at Covalence Research Ltd, which received consulting fees from medac GmbH for model and manuscript development in the present project and for projects outside the present work. Kristin Grabe-Heyne, Anja Rasch, and Annelie Wagner are employed by medac GmbH, which manufacturers and markets methotrexate, including in the UK. Muhammad K. Nisar undertakes clinical trials and received support (including attendance at conferences, speaker fees and honoraria) from AlfaSigma, Medac pharma, Roche, Chugai, MSD, AbbVie, Pfizer, BMS, Novartis, Celgene, UCB, Flynn Pharma and Lilly. Mondher Toumi is the CEO at InovIntell.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"As an economic modelling analysis based on published literature, the present study did not enrol human participants or make use of human biological samples or individually identifiable data, and ethics approval was therefore not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}